XORTX Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XRTX research report →
Price Chart
About the company
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD).
- CEO
- Allen Warren Davidoff
- IPO
- 2021
- Employees
- 2
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on XRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $481.79K
- P/E
- -0.31
- Fwd P/E
- 0.43
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.66
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -126.96%
- ROIC
- -70.27%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-3,256,014
- Net Income
- $-2,656,304+15.8%
- EPS
- $-2.80+48.9%
- OCF Growth
- +23.4%
- FCF Growth
- +24.2%
- 52W High
- $7.05
- 52W Low
- $1.59
- 50D MA
- $2.04
- 200D MA
- $2.28
- Beta
- 0.08
- RSI (14)
- 42
- Avg Volume
- 228.57K
No earnings-call transcripts are available for XRTX yet.
- Free Float
- 89.8%
- Shares Outstanding
- 278.49K
- Float Shares
- 250.02K
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 23.12K | ▲ 23.12K |
| Stonex Group Inc. | 16.37K | ▲ 16.37K |
| Royal Bank Of Canada | 732 | ▲ 732 |
| National Bank Of Canada | 162 | ▲ 162 |
| Clearstead Advisors, LLC | 55 | ▼ 222 |
| Td Waterhouse Canada Inc. | 9 | ▼ 38 |
Our XRTX coverage
Recent articles, reports, and earnings notes.
No research on XRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XRTX report →XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
globenewswire.com · Sep 18
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
globenewswire.com · Sep 10
XORTX Re-Engages Investor Relations Program
globenewswire.com · Sep 8
XORTX Announces Termination and Postponement of Investor Relations Program
globenewswire.com · Aug 28
XORTX Announces Director Resignation
globenewswire.com · Jul 31
XORTX Appoints New Director
globenewswire.com · Jul 29
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
globenewswire.com · Jun 15
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
globenewswire.com · Jun 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.